BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 14, 2005
View Archived Issues
Savient Terminates Phase II Prosaptide Analgesia Study
Savient Pharmaceuticals Inc. has halted its Phase II trial for Prosaptide after an interim analysis indicated the product would not reach its analgesia efficacy endpoint. (BioWorld Today)
Read More
XOMA Anti-Terrorism Deal Provides Needed Stock Hike
Read More
Survival Of Fittest In 2005 For Biotechnology Firms
Read More
Raising $7M, ImaRx Plans To Fund Trials, Add Executives
Read More
Republicans, Democrats Detail Health Care Agendas For 2005
Read More
Other News To Note
Read More
Appointments And Advancements
Read More